LOQTORZI™ (toripalimab-tpzi) LOQTORZI™ (toripalimab-tpzi) product image – Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all…
$95 million in development milestones payable over two years, as part of GSK license agreementCAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE…
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to…
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused…
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has…
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on…
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced…
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s diseaseBETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) --…
BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical studySAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE)…
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…